Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone vs spironolactone in primary aldosteronism
ChiCTR2300069660Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in primary aldosteronism (PA) comparing Finerenone group with Spironolactone group (2 arms). Primary endpoints: Blood pressure, Serum potassium and 1 more. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
finerenonespironolactone
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on ChiCTR2300069660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069660.